A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 68 (final count)
- Started
- Aug 2, 2022
- Main results expected
- Aug 22, 2024
- Fully finished
- Jul 24, 2025
- Results posted
- Oct 3, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: From first dose (Day 1) till 28 days
Number of Participants With Adverse Events
Measured over: From first dose (Day 1) till 30 days after the last dose (Up to approximately 13 months) for Group A to C and from Day 1 untill 100 days after last dose (up to approximately 15 months) for group D
Number of Participants Who Died
Measured over: From first dose (Day 1) until 100 days after the last dose (Up to approximately 15 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05407675 · record last updated 2026-08-13 · checked 2026-11-09 15:47 UTC